The Claim
Urolithin A activates the AMPK signaling pathway and inhibits mTOR activity in cardiac tissue of HFpEF mice, leading to restoration of mitophagic flux and improved mitochondrial respiration.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with heart failure with preserved ejection fraction, urolithin A increases AMPK activity, reduces mTOR activity, restores mitophagy, and improves mitochondrial energy production in heart tissue.
See the scientific wording
Urolithin A activates the AMPK signaling pathway and inhibits mTOR activity in cardiac tissue of HFpEF mice, which is associated with restoration of mitophagic flux and improved mitochondrial respiration, suggesting a mechanistic link between urolithin A and enhanced mitochondrial quality control.
Urolithin A turns on a cellular energy sensor that shuts down a growth signal, which triggers the cleanup of damaged mitochondria. This cleanup improves the mitochondria's ability to produce energy, which helps the heart muscle relax and pump more efficiently.
What the research says
1 studyIn mice with a type of heart failure, a compound called urolithin A helped clean up damaged energy factories in heart cells by turning on a cellular energy alarm (AMPK) and turning off a growth signal (mTOR), which made the heart pump better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.